• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by RAPT Therapeutics Inc.

    3/18/26 9:14:56 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RAPT alert in real time by email
    15-12G 1 d77910d1512g.htm 15-12G 15-12G
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number: 001-38997

     

     

    RAPT Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    561 Eccles Avenue

    South San Francisco, California 94080

    Tel: (650) 489-9000

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common stock, par value $0.0001 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: 1*

     

    *

    Pursuant to an Agreement and Plan of Merger, dated as of January 19, 2026, by and among RAPT Therapeutics, Inc., a Delaware corporation (“Company”), GlaxoSmithKline LLC, a Delaware limited liability company (“Parent”), Redrose Acquisition Co., a Delaware corporation (“Merger Sub”), and solely for the purposes set forth therein, GSK plc, a public limited company organized under the laws of England and Wales, Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

     

     
     


    Pursuant to the requirements of the Securities Exchange Act of 1934, RAPT Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

    Date: March 18, 2026

     

    RAPT THERAPEUTICS, INC.
    By:  

    /s/ Justin Huang

    Name:   Justin Huang
    Title:   President and Secretary
    Get the next $RAPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RAPT

    DatePrice TargetRatingAnalyst
    1/9/2026$95.00Overweight
    Piper Sandler
    10/27/2025$70.00Buy
    Guggenheim
    10/20/2025$55.00Neutral → Overweight
    Analyst
    10/13/2025$35.00Overweight
    Barclays
    9/26/2025$37.00Market Perform → Outperform
    Leerink Partners
    7/30/2025$14.00Underweight → Neutral
    Analyst
    5/22/2025$6.00Buy
    H.C. Wainwright
    12/26/2024$10.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $RAPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons-Williams Lori closing all direct ownership in the company (SEC Form 4)

    4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    3/5/26 9:04:52 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Gray Mary Ann closing all direct ownership in the company (SEC Form 4)

    4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    3/5/26 9:03:18 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Giordano Michael F closing all direct ownership in the company (SEC Form 4)

    4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)

    3/5/26 9:01:13 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

    NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE:GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ:RAPT) in a transaction valued at $2.2 billion. RAPT Therapeutics was a recent, undisclosed investment within Forbion Growth Fund III's public value opportunities strategy and represents the fund's second exit. The transaction follows the acquisition of Astria Therapeutics by BioCryst for $920 million in October 2025, further underscoring the fund's strong momentum and execution capabilities.

    1/20/26 2:13:41 PM ET
    $GSK
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 44thAnnual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific Time. To access the live webcast or subsequent archived recording of the presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presen

    1/7/26 4:05:00 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

    - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W dosing - Completed $250 million public offering to strengthen balance sheet SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial re

    11/6/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    SEC Filings

    View All

    SEC Form 15-12G filed by RAPT Therapeutics Inc.

    15-12G - RAPT Therapeutics, Inc. (0001673772) (Filer)

    3/18/26 9:14:56 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by RAPT Therapeutics Inc.

    EFFECT - RAPT Therapeutics, Inc. (0001673772) (Filer)

    3/5/26 12:15:08 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by RAPT Therapeutics Inc.

    EFFECT - RAPT Therapeutics, Inc. (0001673772) (Filer)

    3/5/26 12:15:04 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on RAPT Therapeutics with a new price target

    Piper Sandler initiated coverage of RAPT Therapeutics with a rating of Overweight and set a new price target of $95.00

    1/9/26 9:07:04 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on RAPT Therapeutics with a new price target

    Guggenheim initiated coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $70.00

    10/27/25 8:48:35 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded RAPT Therapeutics from Neutral to Overweight and set a new price target of $55.00

    10/20/25 12:32:15 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Leadership Updates

    Live Leadership Updates

    View All

    RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

    SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibod

    6/23/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

    SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E ("IgE"), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria ("CSU").

    4/15/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

    1/6/25 8:00:00 AM ET
    $CTNM
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/14/24 1:22:39 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/14/24 9:39:56 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by RAPT Therapeutics Inc.

    SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)

    11/12/24 4:59:18 PM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RAPT
    Financials

    Live finance-specific insights

    View All

    RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

    -  RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing-  Efficacy sustained at Week 16 after a single dose of RPT904-  Well tolerated with no serious adverse events related to study drug-  Jeyou to advance RPT904 to Phase 3 development in China-  RAPT to discuss Phase 3 development path with FDA-  RAPT to host conference call at 8:30 am ET today SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunologica

    10/20/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

    SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025.RAPT will host a webcast co

    10/19/25 8:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

    - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patient

    12/23/24 7:00:00 AM ET
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care